What is Ginkgo Bioworks' operating income?

Ginkgo Bioworks' total operating income in 2025 was -$315.28 million, based on the following breakdown: Total Gross Profit: $123.18 million Total Operating Expenses: $438.46 million

Ginkgo Bioworks (DNA) Financials

$7.56 -0.35 (-4.36%)

Closing price 03:59 PM Eastern

Extended Trading

$7.67 +0.11 (+1.39%)

As of 05:41 PM Eastern

Compare

Annual Income Statements for Ginkgo Bioworks

This table shows Ginkgo Bioworks' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-119	-127	-1,830	-2,105	-893	-546	-313
Consolidated Net Income / (Loss)	-120	-127	-1,837	-2,106	-893	-547	-313
Net Income / (Loss) Continuing Operations	-120	-127	-1,837	-2,106	-893	-547	-313
Total Pre-Tax Income	-120	-125	-1,838	-2,121	-893	-548	-314
Total Operating Income	-72	-137	-1,828	-2,209	-864	-560	-315
Total Gross Profit	54	61	184	273	197	182	123
Total Revenue	54	77	314	478	251	227	170
Operating Revenue	54	77	314	478	251	227	170
Total Cost of Revenue	0.00	16	130	204	54	45	47
Operating Cost of Revenue	0.00	16	130	204	54	45	47
Total Operating Expenses	126	198	2,013	2,482	1,062	742	438
Selling, General & Admin Expense	29	38	863	1,430	385	246	183
Research & Development Expense	96	160	1,150	1,053	581	424	244
Impairment Charge	-	-	0.00	0.00	96	48	0.00
Restructuring Charge	-	-	-	0.00	0.00	24	11
Total Other Income / (Expense), net	-48	12	-9.66	88	-29	12	1.68
Interest Expense	2.42	2.39	2.37	0.11	0.09	0.09	0.00
Interest & Investment Income	-49	-1.55	-88	-45	-43	2.77	6.21
Other Income / (Expense), net	3.16	16	81	133	14	9.57	-4.53
Income Tax Expense	0.02	1.89	-1.48	-15	-0.07	-0.48	-0.84
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-	0.00	0.00	-1.49	0.00
Basic Earnings per Share	($0.10)	($0.10)	($1.35)	($50.15)	($18.37)	($10.54)	($5.64)
Weighted Average Basic Shares Outstanding	1.15B	1.27B	1.36B	41.98M	48.61M	51.89M	55.46M
Diluted Earnings per Share	($0.10)	($0.10)	($1.39)	($50.20)	($18.37)	($10.54)	($5.64)
Weighted Average Diluted Shares Outstanding	1.15B	1.27B	1.36B	42.00M	48.61M	51.89M	55.46M
Weighted Average Basic & Diluted Shares Outstanding	-	-	1.47B	1.95B	2.15B	58.03M	61.92M

This table shows Ginkgo Bioworks' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-303	-212	-175	-229	-55	-109	-91	-69	-81	-65	-83
Consolidated Net Income / (Loss)	-303	-212	-166	-217	-56	-108	-91	-60	-81	-81	-83
Net Income / (Loss) Continuing Operations	-303	-212	-175	-229	-56	-108	-83	-69	-81	-65	-76
Total Pre-Tax Income	-303	-212	-166	-217	-57	-108	-83	-61	-81	-81	-76
Total Operating Income	-286	-178	-178	-226	-55	-104	-81	-70	-90	-66	-71
Total Gross Profit	49	28	20	31	77	34	34	26	26	42	16
Total Revenue	55	35	38	56	89	44	38	50	39	33	19
Operating Revenue	55	35	38	56	89	44	38	50	39	33	19
Total Cost of Revenue	6.92	6.61	18	26	12	9.62	4.09	23	13	-8.51	3.10
Operating Cost of Revenue	6.92	6.61	18	26	12	9.62	4.09	23	13	-8.51	3.10
Total Operating Expenses	335	206	207	265	132	138	115	100	116	97	88
Selling, General & Admin Expense	82	89	70	66	52	57	40	43	45	46	38
Research & Development Expense	157	117	136	134	77	76	71	53	69	50	50
Restructuring Charge	0.00	-	0.00	17	2.95	-	4.47	3.67	1.75	0.71	0.00
Total Other Income / (Expense), net	-17	-34	12	5.95	-1.57	-4.25	-2.25	4.96	9.26	-11	-4.77
Interest Expense	-15	44	-12	-10	-9.25	-	-6.08	-6.08	-5.74	18	-3.60
Interest & Investment Income	-36	3.58	-2.54	-6.83	-6.91	17	-3.69	-0.23	3.68	6.44	-1.21
Other Income / (Expense), net	4.78	6.65	2.96	2.47	-3.91	1.05	-4.64	-0.90	-0.16	0.82	-7.15
Income Tax Expense	-0.02	-0.20	0.03	0.19	-0.38	-0.33	0.09	-0.28	0.00	-0.64	-0.08
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-7.65	-	-	-	-6.53
Basic Earnings per Share	($6.21)	($4.35)	($3.31)	($4.23)	($1.08)	($2.10)	($1.68)	($1.10)	($1.45)	($1.17)	($1.39)
Weighted Average Basic Shares Outstanding	48.77M	48.61M	50.11M	51.37M	52.24M	51.89M	54.24M	54.86M	55.63M	55.46M	59.56M
Weighted Average Diluted Shares Outstanding	48.77M	48.61M	50.13M	51.38M	52.25M	51.89M	58.53M	54.86M	55.63M	55.46M	65.32M
Weighted Average Basic & Diluted Shares Outstanding	2.12B	2.15B	2.21B	2.22B	57.48M	58.03M	58.53M	59.20M	60.59M	61.92M	65.32M

This table details how cash moves in and out of Ginkgo Bioworks' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	291	-113	1,207	-223	-380	-384	-393
Net Cash From Operating Activities	-45	-136	-254	-252	-296	-320	-171
Net Cash From Continuing Operating Activities	-45	-136	-254	-252	-296	-320	-171
Net Income / (Loss) Continuing Operations	-120	-127	-1,837	-2,106	-893	-547	-313
Consolidated Net Income / (Loss)	-120	-127	-1,837	-2,106	-893	-547	-313
Depreciation Expense	11	14	29	43	71	63	59
Non-Cash Adjustments To Reconcile Net Income	63	4.59	1,622	1,878	498	275	136
Changes in Operating Assets and Liabilities, net	1.48	-28	-68	-66	29	-111	-53
Net Cash From Investing Activities	-75	-67	-73	-67	-81	-62	-240
Net Cash From Continuing Investing Activities	-75	-67	-73	-67	-81	-62	-240
Purchase of Property, Plant & Equipment	-22	-58	-57	-52	-41	-63	-7.67
Acquisitions	0.00	0.00	-12	75	0.00	-5.40	0.00
Purchase of Investments	-50	0.00	-5.00	-59	-43	0.00	-419
Sale of Property, Plant & Equipment	-	-	0.00	0.00	4.43	0.65	0.57
Sale and/or Maturity of Investments	-	-	0.30	10	0.00	4.52	185
Other Investing Activities, net	-2.25	-9.30	0.00	-40	-1.34	0.54	0.05
Net Cash From Financing Activities	410	90	1,534	95	-3.22	-1.74	18
Net Cash From Continuing Financing Activities	410	90	1,534	95	-3.22	-1.74	18
Repayment of Debt	-	-	-	-	-0.58	-0.00	0.00
Issuance of Common Equity	0.00	0.00	60	99	0.00	0.00	18
Other Financing Activities, net	-0.35	-0.72	1,499	-2.50	-2.64	-1.74	-0.35
Effect of Exchange Rate Changes	0.00	0.00	-0.02	0.91	-0.59	-0.28	0.20

This table details how cash moves in and out of Ginkgo Bioworks' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-77	-105	-102	-111	-114	-56	-250	-104	-94	55	-24
Net Cash From Operating Activities	-74	-58	-89	-84	-104	-42	-52	-40	-32	-48	-47
Net Cash From Continuing Operating Activities	-74	-58	-89	-84	-104	-42	-43	-40	-32	-48	-46
Net Income / (Loss) Continuing Operations	-303	-212	-166	-217	-56	-108	-83	-60	-81	-81	-76
Depreciation Expense	21	13	13	17	17	16	15	16	14	14	13
Non-Cash Adjustments To Reconcile Net Income	214	101	64	121	37	53	38	30	21	44	31
Changes in Operating Assets and Liabilities, net	-5.24	40	-0.61	-5.28	-101	-3.48	-12	-26	14	-25	-14
Net Cash From Discontinued Operating Activities	-	-	-	-	-	-	-8.77	-	-	-	-0.25
Net Cash From Investing Activities	-3.38	-47	-12	-27	-10	-13	-199	-64	-73	95	23
Net Cash From Continuing Investing Activities	-3.38	-47	-12	-27	-10	-13	-199	-64	-73	95	23
Purchase of Property, Plant & Equipment	-4.38	-3.45	-6.71	-27	-15	-14	-7.62	-0.04	-	-0.01	-1.93
Purchase of Investments	-	-	0.00	-	-	-	-191	-129	-82	-17	-83
Sale and/or Maturity of Investments	-	-	-	-	-	0.57	0.00	-	8.64	112	108
Other Investing Activities, net	0.93	-1.68	0.00	-	0.54	-	0.12	0.14	0.25	-0.46	0.05
Net Cash From Financing Activities	-0.32	-0.63	-0.85	-0.23	-0.47	-0.20	-0.21	-0.10	9.94	8.14	-0.02
Net Cash From Continuing Financing Activities	-0.32	-0.63	-0.85	-0.23	-0.47	-0.20	-0.21	-0.10	9.94	8.14	-0.02
Other Financing Activities, net	-0.31	-0.66	-0.85	-0.23	-0.46	-0.20	-0.21	-0.10	-0.02	-0.03	-0.02
Effect of Exchange Rate Changes	-0.20	0.10	-0.16	-0.02	-0.04	-0.07	0.07	0.19	0.09	-0.15	-0.13

This table presents Ginkgo Bioworks' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	675	2,071	2,539	1,665	1,377	1,120
Total Current Assets	427	1,723	1,450	1,002	603	472
Cash & Equivalents	381	1,550	1,316	944	562	167
Short-Term Investments	-	102	-	-	0.00	255
Accounts Receivable	22	132	82	18	22	24
Prepaid Expenses	21	34	52	40	19	25
Plant, Property, & Equipment, net	121	146	315	188	204	167
Total Noncurrent Assets	127	87	774	475	571	480
Long-Term Investments	29	-	114	79	49	15
Intangible Assets	3.29	22	111	83	73	53
Other Noncurrent Operating Assets	80	44	489	265	450	408
Other Noncurrent Nonoperating Assets	-	-	-	-	-	3.85
Total Liabilities & Shareholders' Equity	675	2,071	2,539	1,665	1,377	1,120
Total Liabilities	205	504	803	568	661	611
Total Current Liabilities	73	135	173	164	107	96
Accounts Payable	14	8.19	10	9.32	14	11
Accrued Expenses	31	93	115	110	65	66
Current Deferred Revenue	29	33	48	44	28	19
Total Noncurrent Liabilities	132	369	630	404	554	515
Noncurrent Deferred Revenue	112	175	175	158	99	75
Other Noncurrent Operating Liabilities	3.03	194	455	246	455	440
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	470	1,567	1,736	1,097	716	509
Total Preferred & Common Equity	461	1,505	1,736	1,097	716	509
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	461	1,505	1,736	1,097	716	509
Common Stock	929	3,805	6,137	6,386	6,555	6,657
Retained Earnings	-468	-2,298	-4,398	-5,291	-5,838	-6,150
Accumulated Other Comprehensive Income / (Loss)	0.00	-1.72	-2.63	1.48	-1.81	1.85

This table presents Ginkgo Bioworks' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	1,871	2,417	2,292	2,026	1,582	1,625	1,481	1,293	1,231	1,189	1,033
Total Current Assets	1,462	1,327	1,223	1,142	903	783	662	565	523	506	410
Cash & Equivalents	1,303	1,206	1,106	1,049	840	730	616	312	204	111	144
Short-Term Investments	-	-	-	-	-	-	-	205	270	351	230
Accounts Receivable	116	85	69	63	25	19	24	27	23	22	20
Prepaid Expenses	38	34	48	29	38	34	22	20	26	22	16
Plant, Property, & Equipment, net	188	314	294	202	196	211	211	198	186	177	163
Total Noncurrent Assets	221	776	774	683	483	631	607	531	522	507	460
Long-Term Investments	4.14	1.19	1.12	86	76	62	62	32	33	30	15
Intangible Assets	48	109	105	100	77	91	80	69	66	62	49
Other Noncurrent Operating Assets	140	607	609	439	281	478	466	430	423	415	393
Other Noncurrent Nonoperating Assets	-	-	-	-	-	-	-	-	-	-	3.21
Total Liabilities & Shareholders' Equity	1,871	2,417	2,292	2,026	1,582	1,625	1,481	1,293	1,231	1,189	1,033
Total Liabilities	431	810	788	774	594	792	683	646	618	629	590
Total Current Liabilities	125	192	163	168	169	166	114	116	97	115	80
Accounts Payable	11	22	14	11	27	23	16	11	11	11	16
Accrued Expenses	73	123	110	115	108	117	76	71	57	79	48
Current Deferred Revenue	41	48	39	43	34	26	23	34	28	25	15
Total Noncurrent Liabilities	306	618	625	605	425	626	569	530	521	514	510
Noncurrent Deferred Revenue	172	175	180	170	166	153	105	80	75	74	78
Other Noncurrent Operating Liabilities	75	443	445	435	259	473	463	450	447	440	432
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,440	1,608	1,504	1,253	987	833	798	647	613	560	443
Total Preferred & Common Equity	1,435	0.00	0.00	1,253	987	833	798	647	613	560	443
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,435	1,608	1,504	1,253	987	833	798	647	613	560	443
Common Stock	5,669	6,212	6,281	6,334	6,445	6,508	6,528	6,577	6,600	6,627	6,675
Retained Earnings	-4,226	-4,603	-4,776	-5,079	-5,456	-5,674	-5,730	-5,929	-5,989	-6,070	-6,233
Accumulated Other Comprehensive Income / (Loss)	-7.91	-1.61	-1.30	-2.90	-1.55	-1.72	0.26	-0.85	1.65	2.00	1.19

This table displays calculated financial ratios and metrics derived from Ginkgo Bioworks' official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	41.48%	309.40%	52.21%	-47.36%	-9.71%	-25.06%
EBITDA Growth	0.00%	-85.57%	-1,505.68%	-18.33%	61.67%	37.51%	46.46%
EBIT Growth	0.00%	-76.66%	-1,345.60%	-18.80%	59.06%	35.28%	41.87%
NOPAT Growth	0.00%	-91.38%	-1,234.38%	-20.81%	60.87%	35.24%	43.68%
Net Income Growth	0.00%	-5.73%	-1,349.34%	-14.69%	57.61%	38.73%	42.83%
EPS Growth	0.00%	0.00%	-1,290.00%	-14.69%	57.61%	42.62%	46.49%
Operating Cash Flow Growth	0.00%	-204.12%	-86.86%	0.64%	-17.17%	-8.15%	46.47%
Free Cash Flow Firm Growth	0.00%	0.00%	-537.07%	-77.67%	80.93%	-13.48%	56.08%
Invested Capital Growth	0.00%	0.00%	-233.33%	399.41%	-75.71%	41.96%	-32.97%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-9.51%	-20.17%	4.17%	-5.79%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	40.74%	2.69%	12.83%	8.75%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	40.11%	2.79%	11.13%	7.78%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	39.69%	5.75%	11.75%	9.79%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	40.47%	-4.52%	16.00%	7.89%
EPS Q/Q Growth	0.00%	0.00%	0.00%	40.47%	-4.52%	15.27%	6.62%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-71.94%	19.48%	13.65%	4.60%	-3.16%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	34.19%	5.19%	3.61%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	59.07%	-36.50%	-11.57%	4.66%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	100.00%	79.64%	58.68%	57.25%	78.52%	80.38%	72.39%
EBITDA Margin	-106.46%	-139.63%	-547.64%	-425.74%	-310.03%	-214.57%	-153.28%
Operating Margin	-132.14%	-178.75%	-582.62%	-462.41%	-343.76%	-246.54%	-185.29%
EBIT Margin	-126.30%	-157.72%	-556.90%	-434.65%	-338.07%	-242.33%	-187.95%
Profit (Net Income) Margin	-221.20%	-165.31%	-585.22%	-440.93%	-355.08%	-240.94%	-183.81%
Tax Burden Percent	100.02%	101.51%	99.92%	99.29%	99.99%	99.91%	99.73%
Interest Burden Percent	175.10%	103.25%	105.17%	102.17%	105.04%	99.51%	98.06%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-249.64%	0.00%	-1,513.72%	-317.41%	-434.65%	-249.82%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-233.97%	0.00%	-1,477.58%	-293.93%	-415.64%	-232.24%
Return on Net Nonoperating Assets (RNNOA)	0.00%	195.72%	0.00%	1,386.20%	254.38%	374.31%	198.74%
Return on Equity (ROE)	0.00%	-53.92%	-180.29%	-127.52%	-63.02%	-60.34%	-51.08%
Cash Return on Invested Capital (CROIC)	0.00%	-449.64%	0.00%	-637.47%	-195.58%	-469.34%	-210.34%
Operating Return on Assets (OROA)	0.00%	-17.91%	-127.29%	-90.07%	-40.44%	-36.16%	-25.61%
Return on Assets (ROA)	0.00%	-18.77%	-133.76%	-91.38%	-42.47%	-35.96%	-25.05%
Return on Common Equity (ROCE)	0.00%	-52.91%	-174.02%	-125.12%	-63.02%	-60.34%	-51.08%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-27.47%	-122.01%	-121.32%	-81.38%	-76.39%	0.00%
Net Operating Profit after Tax (NOPAT)	-50	-96	-1,280	-1,546	-605	-392	-221
NOPAT Margin	-92.50%	-125.13%	-407.83%	-323.69%	-240.63%	-172.58%	-129.70%
Net Nonoperating Expense Percent (NNEP)	0.00%	-15.67%	-53.97%	-36.14%	-23.47%	-19.01%	-17.57%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-89.06%	-55.15%	-54.72%	-43.39%
Cost of Revenue to Revenue	0.00%	20.36%	41.32%	42.75%	21.48%	19.62%	27.61%
SG&A Expenses to Revenue	54.41%	49.97%	274.97%	299.31%	153.12%	108.42%	107.72%
R&D to Revenue	177.73%	208.42%	366.32%	220.35%	230.90%	186.78%	143.27%
Operating Expenses to Revenue	232.14%	258.39%	641.29%	519.66%	422.28%	326.92%	257.68%
Earnings before Interest and Taxes (EBIT)	-68	-121	-1,748	-2,076	-850	-550	-320
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-58	-107	-1,719	-2,034	-780	-487	-261
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	3.25	8.21	1.89	3.26	0.79	0.99
Price to Tangible Book Value (P/TBV)	0.00	3.29	8.45	2.09	3.71	0.88	1.11
Price to Revenue (P/Rev)	27.68	19.57	39.37	6.86	14.24	2.49	2.96
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	14.52	0.00	6.03	34.32	0.00	0.93
Enterprise Value to Revenue (EV/Rev)	0.00	14.55	34.30	3.87	10.17	0.00	0.39
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.04	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.04	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.84	-1.01	-0.94	-0.87	-0.90	-0.86
Leverage Ratio	0.00	1.44	1.35	1.40	1.48	1.68	2.04
Compound Leverage Factor	0.00	1.48	1.42	1.43	1.56	1.67	2.00
Debt to Total Capital	0.00%	3.39%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	3.39%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	1.78%	3.96%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	94.80%	96.04%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.15	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	3.67	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.15	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.17	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	4.10	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.17	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	3.57	11.45	-1.88	-1.60	-6.14	-7.58
Noncontrolling Interest Sharing Ratio	0.00%	1.87%	3.48%	1.88%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	5.83	12.79	8.38	6.11	5.62	4.92
Quick Ratio	0.00	5.50	13.24	8.08	5.87	5.44	4.66
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-173	-1,101	-1,955	-373	-423	-186
Operating Cash Flow to CapEx	-201.01%	-234.91%	-449.07%	-482.48%	-812.42%	-516.35%	-2,412.34%
Free Cash Flow to Firm to Interest Expense	0.00	-72.44	-463.81	-18,447.87	-4,009.08	-4,501.04	0.00
Operating Cash Flow to Interest Expense	-18.45	-56.95	-106.96	-2,379.23	-3,177.42	-3,399.84	0.00
Operating Cash Flow Less CapEx to Interest Expense	-27.63	-81.20	-130.78	-2,872.35	-3,568.53	-4,058.28	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.11	0.23	0.21	0.12	0.15	0.14
Accounts Receivable Turnover	0.00	3.50	4.09	4.46	5.01	11.26	7.29
Inventory Turnover	0.00	5.71	42.54	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.63	2.35	2.07	1.00	1.16	0.92
Accounts Payable Turnover	0.00	1.12	11.75	21.91	5.46	3.79	3.80
Days Sales Outstanding (DSO)	0.00	104.30	89.23	81.76	72.84	32.43	50.09
Days Inventory Outstanding (DIO)	0.00	63.97	8.58	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	324.83	31.07	16.66	66.82	96.24	96.10
Cash Conversion Cycle (CCC)	0.00	-156.56	66.74	65.10	6.02	-63.81	-46.02
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	77	-102	307	75	106	71
Invested Capital Turnover	0.00	2.00	-24.51	4.68	1.32	2.52	1.93
Increase / (Decrease) in Invested Capital	0.00	77	-179	409	-232	31	-35
Enterprise Value (EV)	0.00	1,115	10,765	1,849	2,558	-46	66
Market Capitalization	1,500	1,500	12,355	3,279	3,580	564	504
Book Value per Share	$0.00	$0.36	$1.01	$0.90	$0.52	$12.46	$8.39
Tangible Book Value per Share	$0.00	$0.36	$0.98	$0.81	$0.46	$11.20	$7.45
Total Capital	0.00	487	1,567	1,736	1,097	716	509
Total Debt	0.00	17	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	17	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-393	-1,652	-1,430	-1,023	-610	-438
Capital Expenditures (CapEx)	22	58	57	52	36	62	7.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-27	-64	-39	-106	-66	-47
Debt-free Net Working Capital (DFNWC)	0.00	353	1,588	1,277	838	495	376
Net Working Capital (NWC)	0.00	353	1,588	1,277	838	495	376
Net Nonoperating Expense (NNE)	70	31	557	560	288	155	92
Net Nonoperating Obligations (NNO)	0.00	-393	-1,670	-1,430	-1,023	-610	-438
Total Depreciation and Amortization (D&A)	11	14	29	43	71	63	59
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-35.85%	-20.32%	-8.10%	-42.23%	-29.11%	-27.48%
Debt-free Net Working Capital to Revenue	0.00%	460.91%	506.09%	267.34%	333.22%	218.23%	220.90%
Net Working Capital to Revenue	0.00%	460.91%	506.09%	267.34%	333.22%	218.23%	220.90%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($54.00)	($50.00)	($18.40)	($10.54)	($5.64)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	34.00M	41.98M	48.61M	51.89M	55.46M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($55.60)	($50.00)	($18.40)	($10.54)	($5.64)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	34.01M	42.00M	48.61M	51.89M	55.46M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	36.79M	48.81M	53.81M	58.03M	61.92M
Normalized Net Operating Profit after Tax (NOPAT)	-50	-96	-1,280	-1,546	-538	-341	-213
Normalized NOPAT Margin	-92.50%	-125.13%	-407.83%	-323.69%	-213.85%	-150.37%	-125.01%
Pre Tax Income Margin	-221.16%	-162.85%	-585.69%	-444.08%	-355.11%	-241.15%	-184.30%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	-28.27	-50.69	-736.52	-19,588.19	-9,140.86	-5,853.04	0.00
NOPAT to Interest Expense	-20.70	-40.22	-539.37	-14,587.42	-6,506.28	-4,168.40	0.00
EBIT Less CapEx to Interest Expense	-37.45	-74.94	-760.34	-20,081.31	-9,531.97	-6,511.48	0.00
NOPAT Less CapEx to Interest Expense	-29.88	-64.46	-563.19	-15,080.54	-6,897.39	-4,826.84	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.34%	0.00%	-1.36%	-0.07%	-0.07%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Ginkgo Bioworks' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	58,531,877.00	59,199,753.00	-	61,924,352.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	58,531,877.00	59,199,753.00	-	61,924,352.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-1.18	-1.36	-	-1.33
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-16.52%	-64.64%	-52.98%	-30.24%	60.65%	26.16%	27.34%	-11.75%	-56.39%	-23.84%	-49.06%
EBITDA Growth	60.47%	11.95%	15.82%	-21.10%	86.59%	45.22%	51.97%	73.16%	-81.21%	32.70%	7.16%
EBIT Growth	57.85%	12.44%	17.28%	-18.91%	81.50%	40.19%	46.72%	68.18%	-52.55%	29.30%	8.28%
NOPAT Growth	56.27%	22.85%	17.49%	-21.07%	80.72%	41.83%	50.02%	68.92%	-63.06%	34.17%	11.85%
Net Income Growth	54.80%	-22.31%	19.06%	-25.31%	81.38%	49.20%	45.18%	72.24%	-43.18%	24.91%	9.20%
EPS Growth	54.80%	-22.31%	27.27%	-22.22%	82.61%	51.72%	49.40%	74.00%	-34.26%	29.94%	0.00%
Operating Cash Flow Growth	-159.34%	44.68%	1.46%	-14.76%	-40.72%	26.62%	42.28%	52.30%	69.46%	-12.36%	9.38%
Free Cash Flow Firm Growth	83.82%	118.84%	149.84%	168.86%	67.26%	-196.50%	-143.83%	-158.40%	72.80%	88.88%	95.95%
Invested Capital Growth	-39.15%	-75.71%	-82.31%	-89.86%	1.94%	41.96%	38.87%	165.07%	-43.37%	-32.97%	-47.34%
Revenue Q/Q Growth	-31.20%	-37.30%	9.18%	48.13%	58.43%	-50.76%	10.20%	2.66%	-21.71%	-14.01%	-41.69%
EBITDA Q/Q Growth	-55.31%	39.12%	-2.24%	-25.26%	82.80%	-148.76%	10.37%	28.80%	-37.06%	32.31%	-27.73%
EBIT Q/Q Growth	-51.89%	39.11%	-2.09%	-25.95%	76.37%	-96.83%	9.07%	23.60%	-26.56%	27.79%	-20.59%
NOPAT Q/Q Growth	-55.52%	37.81%	0.06%	-25.25%	75.24%	-87.68%	14.13%	20.92%	-27.95%	26.75%	-8.25%
Net Income Q/Q Growth	-74.76%	30.11%	21.63%	-30.90%	74.03%	-90.65%	15.42%	33.70%	-33.92%	0.01%	-2.27%
EPS Q/Q Growth	-74.76%	30.11%	27.27%	-37.50%	-881.82%	-94.44%	20.00%	34.52%	-31.82%	19.31%	0.00%
Operating Cash Flow Q/Q Growth	-0.02%	21.37%	-54.34%	5.45%	-22.65%	59.00%	-21.41%	21.87%	21.48%	-50.85%	2.08%
Free Cash Flow Firm Q/Q Growth	57.06%	186.06%	90.50%	-2.20%	-120.42%	-153.65%	13.48%	-28.77%	90.37%	-1.31%	69.74%
Invested Capital Q/Q Growth	-70.42%	-36.50%	-4.97%	-43.21%	197.47%	-11.57%	-7.04%	8.41%	-36.45%	4.66%	-26.97%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.51%	80.98%	75.75%	75.59%	86.52%	78.06%	60.12%	52.82%	67.04%	125.47%	84.09%
EBITDA Margin	-470.05%	-456.43%	-427.41%	-361.43%	-39.23%	-198.20%	-161.20%	-111.80%	-195.72%	-154.07%	-337.49%
Operating Margin	-516.68%	-512.49%	-469.12%	-396.66%	-61.99%	-236.29%	-184.13%	-141.84%	-231.78%	-197.44%	-366.51%
EBIT Margin	-508.04%	-493.37%	-461.33%	-392.27%	-58.51%	-233.90%	-193.01%	-143.64%	-232.20%	-194.98%	-403.21%
Profit (Net Income) Margin	-546.44%	-609.10%	-437.25%	-386.40%	-63.34%	-245.25%	-188.25%	-121.56%	-207.93%	-241.80%	-424.09%
Tax Burden Percent	99.99%	99.91%	100.02%	100.09%	99.34%	99.70%	100.10%	99.53%	100.00%	99.21%	108.47%
Interest Burden Percent	107.57%	123.57%	94.76%	98.42%	108.97%	105.17%	97.44%	85.03%	89.55%	125.00%	96.97%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-734.53%	-473.20%	-290.93%	-234.30%	-79.83%	-416.58%	-361.84%	-312.18%	-312.78%	-266.20%	-517.50%
ROIC Less NNEP Spread (ROIC-NNEP)	-725.93%	-466.10%	-287.04%	-227.87%	-77.87%	-412.29%	-357.93%	-310.48%	-309.74%	-259.60%	-510.56%
Return on Net Nonoperating Assets (RNNOA)	642.30%	403.39%	234.93%	185.26%	68.87%	371.29%	320.89%	278.96%	267.00%	222.14%	440.29%
Return on Equity (ROE)	-92.23%	-69.82%	-56.01%	-49.04%	-10.96%	-45.28%	-40.95%	-33.22%	-45.78%	-44.06%	-77.22%
Cash Return on Invested Capital (CROIC)	-365.27%	-195.58%	-105.77%	-114.15%	-376.63%	-469.34%	-422.17%	-390.52%	-205.76%	-210.34%	-223.07%
Operating Return on Assets (OROA)	-82.13%	-59.01%	-48.15%	-36.92%	-7.27%	-34.91%	-31.87%	-23.22%	-31.41%	-26.57%	-52.48%
Return on Assets (ROA)	-88.33%	-72.85%	-45.64%	-36.37%	-7.87%	-36.60%	-31.09%	-19.65%	-28.13%	-32.95%	-55.20%
Return on Common Equity (ROCE)	-92.05%	-69.82%	-56.01%	-49.04%	-10.96%	-45.28%	-40.95%	-33.22%	-45.78%	-44.06%	-77.22%
Return on Equity Simple (ROE_SIMPLE)	-68.19%	0.00%	-86.48%	-107.76%	-81.61%	0.00%	-72.92%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-200	-125	-125	-156	-39	-73	-62	-49	-63	-46	-50
NOPAT Margin	-361.67%	-358.75%	-328.38%	-277.66%	-43.40%	-165.40%	-128.89%	-99.28%	-162.25%	-138.21%	-256.56%
Net Nonoperating Expense Percent (NNEP)	-8.60%	-7.10%	-3.89%	-6.43%	-1.96%	-4.29%	-3.91%	-1.70%	-3.03%	-6.60%	-6.94%
Return On Investment Capital (ROIC_SIMPLE)	-	-11.36%	-	-	-	-10.13%	-9.62%	-8.03%	-11.26%	-9.08%	-11.27%
Cost of Revenue to Revenue	12.49%	19.02%	24.25%	24.41%	13.48%	21.94%	39.88%	47.18%	32.96%	-25.47%	15.91%
SG&A Expenses to Revenue	147.98%	256.72%	185.24%	117.93%	58.72%	130.67%	101.50%	87.25%	115.75%	137.78%	194.26%
R&D to Revenue	282.63%	336.75%	359.63%	238.80%	86.48%	174.19%	146.78%	107.59%	178.57%	150.10%	256.34%
Operating Expenses to Revenue	604.19%	593.47%	544.87%	472.25%	148.52%	314.35%	259.20%	202.25%	298.82%	290.00%	450.60%
Earnings before Interest and Taxes (EBIT)	-282	-171	-175	-220	-52	-103	-93	-71	-90	-65	-79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-261	-159	-162	-203	-35	-87	-78	-55	-76	-51	-66
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.86	3.26	2.53	0.89	0.57	0.79	0.51	1.07	1.54	0.99	0.86
Price to Tangible Book Value (P/TBV)	3.27	3.71	2.90	1.00	0.63	0.88	0.57	1.20	1.73	1.11	0.96
Price to Revenue (P/Rev)	11.37	14.24	11.96	4.01	2.08	2.49	1.39	2.85	4.78	2.96	2.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	20.85	34.32	22.32	0.00	0.00	0.00	0.00	1.43	5.48	0.93	0.00
Enterprise Value to Revenue (EV/Rev)	7.77	10.17	7.57	0.00	0.00	0.00	0.00	0.66	2.05	0.39	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.88	-0.87	-0.82	-0.81	-0.88	-0.90	-0.90	-0.90	-0.86	-0.86	-0.86
Leverage Ratio	1.45	1.48	1.54	1.68	1.71	1.68	1.76	1.98	1.97	2.04	2.13
Compound Leverage Factor	1.56	1.83	1.46	1.65	1.86	1.76	1.71	1.68	1.76	2.55	2.07
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.46	-0.25	-1.99	-4.21	-4.54	-5.07	-5.75	-5.76	-6.03	-6.83	-7.78
Noncontrolling Interest Sharing Ratio	0.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.78	6.11	5.34	4.71	5.79	5.62	4.88	5.41	4.39	4.92	5.15
Quick Ratio	6.60	5.87	5.12	4.51	5.59	5.44	4.70	5.14	4.20	4.66	4.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-125	108	205	200	-41	-104	-90	-116	-11	-11	-3.41
Operating Cash Flow to CapEx	-1,707.71%	-2,865.76%	-1,330.24%	-312.19%	-704.62%	-310.81%	-675.95%	-105,931.58%	0.00%	0.00%	-2,415.21%
Free Cash Flow to Firm to Interest Expense	0.00	2.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.63	0.00
Operating Cash Flow to Interest Expense	0.00	-1.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.66	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-1.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.63	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.16	0.12	0.10	0.09	0.12	0.15	0.17	0.16	0.14	0.14	0.13
Accounts Receivable Turnover	3.52	5.01	3.82	4.20	5.01	11.26	9.18	10.99	7.80	7.29	6.38
Inventory Turnover	26.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.62	1.00	0.82	0.73	1.06	1.16	1.21	1.16	0.93	0.92	0.84
Accounts Payable Turnover	7.03	5.46	1.68	1.99	3.14	3.79	2.37	2.53	3.34	3.80	3.33
Days Sales Outstanding (DSO)	103.65	72.84	95.67	86.93	72.92	32.43	39.76	33.22	46.79	50.09	57.18
Days Inventory Outstanding (DIO)	13.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	51.91	66.82	217.07	183.51	116.23	96.24	153.76	144.31	109.29	96.10	109.45
Cash Conversion Cycle (CCC)	65.69	6.02	-121.40	-96.58	-43.31	-63.81	-114.00	-111.08	-62.51	-46.02	-52.27
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	117	75	71	40	120	106	98	107	68	71	52
Invested Capital Turnover	2.03	1.32	0.89	0.84	1.84	2.52	2.81	3.14	1.93	1.93	2.02
Increase / (Decrease) in Invested Capital	-75	-232	-330	-356	2.28	31	28	66	-52	-35	-47
Enterprise Value (EV)	2,446	2,558	1,580	-54	-225	-46	-218	152	371	66	-8.56
Market Capitalization	3,582	3,580	2,497	739	453	564	331	658	863	504	380
Book Value per Share	$0.63	$0.52	$0.46	$0.38	$0.36	$12.46	$11.16	$10.47	$9.46	$8.39	$7.16
Tangible Book Value per Share	$0.55	$0.46	$0.40	$0.34	$0.32	$11.20	$9.97	$9.34	$8.42	$7.45	$6.37
Total Capital	1,253	1,097	987	833	798	716	647	613	560	509	443
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,135	-1,023	-916	-793	-678	-610	-549	-506	-492	-438	-388
Capital Expenditures (CapEx)	4.31	2.02	6.71	27	15	14	7.62	0.04	0.00	-0.57	1.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-76	-106	-106	-113	-68	-66	-68	-47	-71	-47	-43
Debt-free Net Working Capital (DFNWC)	973	838	734	617	548	495	449	426	391	376	330
Net Working Capital (NWC)	973	838	734	617	548	495	449	426	391	376	330
Net Nonoperating Expense (NNE)	102	87	41	61	18	35	29	11	18	35	33
Net Nonoperating Obligations (NNO)	-1,135	-1,023	-916	-793	-678	-610	-549	-506	-492	-438	-391
Total Depreciation and Amortization (D&A)	21	13	13	17	17	16	15	16	14	14	13
Debt-free, Cash-free Net Working Capital to Revenue	-24.08%	-42.23%	-51.01%	-61.39%	-31.27%	-29.11%	-28.66%	-20.53%	-39.35%	-27.48%	-28.47%
Debt-free Net Working Capital to Revenue	309.03%	333.22%	351.70%	334.83%	251.46%	218.23%	189.06%	184.70%	216.38%	220.90%	218.20%
Net Working Capital to Revenue	309.03%	333.22%	351.70%	334.83%	251.46%	218.23%	189.06%	184.70%	216.38%	220.90%	218.20%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($6.40)	($174.00)	($3.20)	($4.40)	($1.08)	($2.10)	($1.68)	($1.10)	($1.45)	($1.17)	($1.39)
Adjusted Weighted Average Basic Shares Outstanding	48.77M	1.22M	50.11M	51.37M	52.24M	51.89M	54.24M	54.86M	55.63M	55.46M	59.56M
Adjusted Diluted Earnings per Share	($6.40)	($174.00)	($3.20)	($4.40)	($1.08)	($2.10)	($1.68)	($1.10)	($1.45)	($1.17)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	48.77M	1.22M	50.13M	51.38M	52.25M	51.89M	54.24M	54.86M	55.63M	55.46M	65.32M
Adjusted Basic & Diluted Earnings per Share	$0.00	($174.00)	$0.00	$0.00	$0.00	($2.10)	$0.00	$0.00	$0.00	($1.17)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	52.96M	53.81M	55.28M	55.58M	57.48M	58.03M	58.53M	59.20M	60.59M	61.92M	65.32M
Normalized Net Operating Profit after Tax (NOPAT)	-133	-125	-125	-111	-37	-73	-59	-47	-62	-46	-50
Normalized NOPAT Margin	-240.17%	-358.75%	-328.38%	-196.80%	-41.08%	-165.40%	-121.25%	-94.10%	-159.10%	-136.73%	-256.56%
Pre Tax Income Margin	-546.48%	-609.67%	-437.17%	-386.06%	-63.76%	-245.99%	-188.06%	-122.13%	-207.93%	-243.72%	-390.98%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-3.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.64	0.00
NOPAT to Interest Expense	0.00	-2.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.58	0.00
EBIT Less CapEx to Interest Expense	0.00	-3.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.60	0.00
NOPAT Less CapEx to Interest Expense	0.00	-2.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.55	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Ginkgo Bioworks (NYSE: DNA) remains a cash-rich but deeply loss-making company. Over the last several years, revenue has been volatile and has not been enough to offset heavy operating expenses, especially R&D and SG&A. The good news is that the balance sheet still shows substantial liquidity. The bad news is that operating losses and cash burn remain the central issue for investors.

The company still has a large liquidity cushion, with $143.9 million of cash and equivalents plus $229.6 million of short-term investments at the end of Q1 2026.
Total current assets were $410.0 million in Q1 2026, which gives DNA some near-term flexibility despite losses.
Ginkgo generated positive investing cash flow in Q1 2026, helped by selling/maturing investments, which offset operating cash burn in the quarter.
Revenue in Q1 2026 was $19.5 million, up from $17.1 million in the prior quarter’s implied run-rate? Actually, compared with Q4 2025’s reported $33.4 million, revenue was lower, but the company is still producing meaningful quarterly sales versus earlier years.
Deferred revenue remains material, with $14.9 million current and $77.9 million noncurrent in Q1 2026, which can support future recognized revenue.
The company’s asset base is still large, including $163.0 million in net PP&E and significant noncurrent operating assets, reflecting a sizable operating footprint.
Basic shares outstanding have come down from prior periods, but dilution remains a recurring theme for shareholders.
DNA reported a Q1 2026 net loss of $82.6 million attributable to common shareholders, or -$1.39 per share.
Operating income was a loss of $71.4 million in Q1 2026, showing the core business is still far from profitability.
Cash from operations was negative $46.7 million in Q1 2026, indicating continued cash burn from the business itself.
Revenue has been inconsistent over the last four years, peaking in some quarters but lacking a clear durable growth trend.
Expenses remain very high relative to revenue: in Q1 2026, SG&A was $37.8 million and R&D was $49.9 million versus only $19.5 million of revenue.
The long-term trend shows persistent losses, with quarterly net income losses repeatedly ranging from roughly $60 million to more than $300 million in earlier periods.

Trend summary: DNA has improved its liquidity position compared with the worst cash burn periods in 2024, but it is still operating at a substantial loss. Revenue remains too small and too uneven to absorb the company’s operating cost base. For retail investors, the key question is not whether the company has cash today, but whether management can scale revenue fast enough to narrow losses before liquidity becomes a bigger concern.

07/20/26 02:56 PM ETAI Generated. May Contain Errors.

Ginkgo Bioworks Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Ginkgo Bioworks' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Ginkgo Bioworks' net income appears to be on an upward trend, with a most recent value of -$312.76 million in 2025, rising from -$119.86 million in 2019. The previous period was -$547.03 million in 2024. See Ginkgo Bioworks' forecast for analyst expectations on what's next for the company.

Ginkgo Bioworks' total operating income in 2025 was -$315.28 million, based on the following breakdown:

Total Gross Profit: $123.18 million
Total Operating Expenses: $438.46 million

Over the last 6 years, Ginkgo Bioworks' total revenue changed from $54.18 million in 2019 to $170.16 million in 2025, a change of 214.0%.

Ginkgo Bioworks' total liabilities were at $611.11 million at the end of 2025, a 7.6% decrease from 2024, and a 198.0% increase since 2020.

In the past 5 years, Ginkgo Bioworks' cash and equivalents has ranged from $167.20 million in 2025 to $1.55 billion in 2021, and is currently $167.20 million as of their latest financial filing in 2025.

Over the last 6 years, Ginkgo Bioworks' book value per share changed from 0.00 in 2019 to 8.39 in 2025, a change of 839.4%.

Related Companies

Financial statements for NYSE:DNA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Financials

Financials Breakdown Chart

Key Financial Trends

Ginkgo Bioworks Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Financials

Annual Income Statements for Ginkgo Bioworks

Quarterly Income Statements for Ginkgo Bioworks

Annual Cash Flow Statements for Ginkgo Bioworks

Quarterly Cash Flow Statements for Ginkgo Bioworks

Annual Balance Sheets for Ginkgo Bioworks

Quarterly Balance Sheets for Ginkgo Bioworks

Annual Metrics And Ratios for Ginkgo Bioworks

Quarterly Metrics And Ratios for Ginkgo Bioworks

Financials Breakdown Chart

Key Financial Trends

Ginkgo Bioworks Financials - Frequently Asked Questions

When does Ginkgo Bioworks' financial year end?

How has Ginkgo Bioworks' net income changed over the last 6 years?

What is Ginkgo Bioworks' operating income?

How has Ginkgo Bioworks' revenue changed over the last 6 years?

How much debt does Ginkgo Bioworks have?

How much cash does Ginkgo Bioworks have?

How has Ginkgo Bioworks' book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools